Updated on 2025/10/23

写真a

 
SUGIMOTO Yukio
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Associate Professor
Position
Associate Professor
External link

Degree

  • Doctor (Pharmaceutical Sciences) ( Okayama University )

  • 博士(薬学) ( 岡山大学 )

Research Interests

  • ヒスタミン

  • アレルギー

  • Histamine

  • Allergy

Research Areas

  • Life Science / Immunology

  • Life Science / Pharmacology

  • Life Science / Pharmaceutical hygiene and biochemistry

Education

  • Okayama University    

    - 1988

    　 More details

  • Okayama University   薬学研究科  

    - 1988

    　 More details

    Country： Japan

    researchmap

  • Okayama University   薬学部   製薬化

    - 1986

    　 More details

    Country： Japan

    researchmap

  • Okayama University    

    - 1986

    　 More details

Research History

  • - 岡山大学医歯薬学総合研究科 准教授

    2004

    　 More details

  • - Associate Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2004

    　 More details

Professional Memberships

Committee Memberships

  • 日本薬学会   ファルマシア 連絡委員  

    2015   

    　 More details

    Committee type：Academic society

    日本薬学会

    researchmap

  • 日本薬学会   ファルマシア トピックス専門小委員  

    2009 - 2011   

    　 More details

    Committee type：Academic society

    日本薬学会

    researchmap

  • 日本薬理学会   学術評議員  

    1999   

    　 More details

    Committee type：Academic society

    日本薬理学会

    researchmap

 

Papers

  • Evaluation methods using tear volume in a conjunctivitis mice model. Reviewed International journal

    Haruki Kai, Noriaki Haraoka, Yukio Sugimoto

    Journal of pharmacological and toxicological methods   128   107520 - 107520   2024

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Allergic conjunctival disease is an immune-mediated inflammatory disease of the conjunctiva. To develop clinically useful drugs, it is necessary to develop quantitative evaluation methods that reflect the clinical symptoms in experimental animal models. Allergic conjunctivitis model mice were systemically sensitised with ovalbumin (OVA) administered intraperitoneally and locally sensitised with OVA eye drops between day 14-28. Next, conjunctivitis induced by ocular administration of OVA solution to sensitised mice was evaluated based on tear volume. Additionally, we evaluated increase in tear volume induced by direct ocular instillation of histamine, compound 48/80, and carrageenan. An increase in antigen-induced tear volume was observed in the mice model. Additionally, direct instillation of histamine, compound 48/80, and carrageenan increased tear volume. Furthermore, levocabastine inhibited the increase in tear volume in antigen-induced allergic conjunctivitis and histamine- and compound 48/80-induced conjunctivitis models. In contrast, betamethasone suppressed carrageenan-induced tear volume but not histamine- or compound 48/80-induced tear volume. Histamine may be involved in increased tear volume in allergic conjunctivitis. Betamethasone is not directly involved in the action of histamine and is thought to suppress increase in tear volume. Evaluation of tear volume in a conjunctivitis mice model is highly quantitative; therefore, it is possible to evaluate drug efficacy. This is considered a useful index compared with conventional methods.

    DOI： 10.1016/j.vascn.2024.107520

    PubMed

    researchmap

  • A mouse model of food allergy permitting skin and nasal symptoms Reviewed

    Takafumi Morinaga, Takuya Yamamoto, Yukio Sugimoto

    Advances in Medical Sciences   68 ( 2 )   372 - 378   2023.9

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.advms.2023.09.012

    researchmap

  • A mouse model of allergic conjunctivitis permitting tear eosinophil quantification. Reviewed International journal

    Atsushi Ogura, Yukio Sugimoto

    Journal of pharmacological and toxicological methods   118   107225 - 107225   2022

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.vascn.2022.107225

    Scopus

    PubMed

    researchmap

  • Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice. Reviewed International journal

    Atsuki Yamamoto, Hiroki Kakuta, Yukio Sugimoto

    International immunopharmacology   22 ( 1 )   204 - 8   2014.9

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Glucocorticoids are effective anti-inflammatory agents widely used for the treatment of acute and chronic inflammatory diseases. Recent in vitro studies have proposed that glucocorticoid receptor (GR) activation is involved in peroxisome proliferator-activated receptor γ (PPARγ) agonist-induced effects. In this study, to examine the involvement of the GR in PPARγ agonist- and retinoid X receptor (RXR) agonist-mediated anti-inflammatory effects in vivo, we tested the anti-inflammatory effects of dexamethasone (a GR agonist) with pioglitazone (a PPARγ agonist) or 6-[N-ethyl-N-(3-isopropoxy-4-isopropylphenyl)-amino] nicotinic acid (NEt-3IP; an RXR agonist) by using an experimental model of carrageenan-induced inflammation. We also evaluated the effects of a GR antagonist on PPARγ agonist- or RXR agonist-induced anti-inflammatory effects. Results showed that the GR antagonist RU486 reduced the anti-inflammatory effects of GR or PPARγ agonists but not those of the RXR agonist. In addition, combinations of GR and PPARγ agonists or GR and RXR agonists had no effect on carrageenan-induced paw edema. Moreover, the PPARγ antagonist GW9662 and RXR antagonist 6-[N-4-(trifluoromethyl)-benzenesulfonyl-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-amino] nicotinic acid (NS-4TF) had no effect on the anti-inflammatory effect of the GR agonist dexamethasone. Therefore, it is suggested that GR activation in vivo does not play a direct role in PPARγ/RXR heterodimer signaling. In contrast, pioglitazone showed a partial anti-inflammatory effect via GR activation. These data provide evidence for the pro-inflammatory activity of pioglitazone.

    DOI： 10.1016/j.intimp.2014.06.028

    PubMed

    researchmap

  • Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice. Reviewed International journal

    Eriko Kusaka, Mayu Sugiyama, Norie Senoo, Atsuki Yamamoto, Yukio Sugimoto

    International immunopharmacology   16 ( 2 )   279 - 87   2013.6

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Glucocorticoids (GCs) are well known for their anti-inflammatory effects, which are elicited through a transcriptional mechanism via a cytosolic glucocorticoid receptor (cGR)-mediated genomic effect. However, recent in vitro studies report that GCs can act as a membrane glucocorticoid receptor (mGR). This study aimed to examine whether mometasone furoate (MF) influences the nasal symptoms induced by histamine, substance P, ATP. Furthermore, the influences of various compounds on MF action were studied in vivo. The mice were intranasally administered with nasal symptom-inciting agents, and the occurrences of sneezing and nasal rubbing were counted. MF repressed the nasal symptoms caused when it was administered 10, 30 and 60min before the induction of nasal symptoms. The repressive effect observed 10min after the administration of MF was inhibited by RU486, a GR antagonist, but not by actinomycin D, a transcriptional inhibitor. In contrast, the repressive effect observed 60min after the administration of MF was inhibited by RU486 and actinomycin D. Therefore, the effects observed 10 and 60min after the MF administration were classified as non-genomic and genomic effects, respectively. The non-genomic effect suppressed the nasal symptoms induced by m-3M3FBS, a phospholipase C (PLC) activator, and was inhibited by U-73122, a PLC inhibitor. The genomic effect was inhibited by N-(p-amylcinnamoyl) anthranilic acid, a phospholipase A2 (PLA2) inhibitor. These results indicate that MF has a non-genomic effect through repression of the activation of PLC via the mGR, and MF has also a genomic effect that was influenced by the inhibition of PLA2 through transcriptional regulation via cGR.

    DOI： 10.1016/j.intimp.2013.03.030

    PubMed

    researchmap

  • In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Reviewed International journal

    Hidekazu Ishimoto, Mari Shibata, Yuki Myojin, Hideyuki Ito, Yukio Sugimoto, Akihiro Tai, Tsutomu Hatano

    Bioorganic & medicinal chemistry letters   21 ( 19 )   5901 - 4   2011.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Urolithin A is a major metabolite produced by rats and humans after consumption of pomegranate juice or pure ellagitannin geraniin. In this study, we investigated the anti-inflammatory effect of urolithin A on carrageenan-induced paw edema in mice. The volume of paw edema was reduced at 1h after oral administration of urolithin A. In addition, plasma in treated mice exhibited significant oxygen radical antioxidant capacity (ORAC) scores with high plasma levels of the unconjugated form at 1h after oral administration of urolithin A. These results indicate strong associations among plasma urolithin A levels, the plasma ORAC scores, and anti-inflammatory effects and may help explain a mechanism by which ellagitannins confer protection against inflammatory diseases.

    DOI： 10.1016/j.bmcl.2011.07.086

    PubMed

    researchmap

  • Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice. Reviewed

    Yuh Suzuki, Toshio Inoue, Atsuki Yamamoto, Yukio Sugimoto

    Biological & pharmaceutical bulletin   34 ( 4 )   507 - 10   2011

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    The prophylactic use of anti-allergic drugs has been proposed to be effective in the treatment of seasonal allergic rhinitis in humans. However, there is little information regarding the prophylactic effect of thromboxane A(2) (TXA(2)) receptor antagonist on allergic rhinitis. Recent studies revealed that a TXA(2) receptor antagonist ramatroban could block the prostaglandin D(2) (PGD(2)) receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). In the present study, we investigated the prophylactic effects of the histamine H(1) receptor antagonist epinastine and the TXA(2) receptor antagonist ramatroban and seratrodast on mouse models of allergic rhinitis. Female BALB/c mice were sensitized by an intraperitoneal injection of ovalbumin and alum on days 0, 5, 14 and 21. Seven days later, mice were sensitized by intranasal application of ovalbumin thrice a week. Drugs were administered once a day from day 22. The severity of allergic rhinitis was assessed by determining the extent of 2 nasal allergic symptoms (sneezing and nasal rubbing). Histamine sensitivity and eosinophil infiltration into the nasal mucosa were also determined. Epinastine and ramatroban significantly reduced nasal symptoms and the number of eosinophils in the nasal mucosa. Seratrodast showed no effect on nasal symptoms and eosinophil infiltration into the nasal mucosa. In addition, histamine sensitivity was reduced by epinastine and ramatroban. These results indicate that epinastine and ramatroban induce the prophylactic effect on allergic rhinitis.

    PubMed

    researchmap

  • Involvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In Vivo. Reviewed International journal

    Atsuki Yamamoto, Hiroki Kakuta, Hiroyuki Miyachi, Yukio Sugimoto

    PPAR research   2011   840194 - 840194   2011

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Peroxisome proliferator-activated receptor γ (PPARγ) forms a heterodimeric DNA-binding complex with retinoid X receptors (RXRs). It has been reported that the effect of the PPAR agonist is reduced in hepatocyte RXR-deficient mice. Therefore, it is suggested that the endogenous RXR ligand is involved in the PPARγ agonist-induced anti-inflammatory effect. However, the participation of the RXR ligand in the PPARγ-induced anti-inflammatory effect is unknown. Here, we investigated the influence of RXR antagonist on the anti-inflammatory effect of PPARγ agonist pioglitazone in carrageenan test. In addition, we also examined the influence of PPAR antagonist on the anti-inflammatory effect induced by RXR agonist NEt-3IP. The RXR antagonist suppressed the antiedema effect of PPARγ agonist. In addition, the anti-inflammatory effect of RXR agonist was suppressed by PPARγ antagonist. PPARγ agonist-induced anti-inflammatory effects were reversed by the RXR antagonist. Thus, we showed that the endogenous RXR ligand might contribute to the PPARγ agonist-induced anti-inflammatory effect.

    DOI： 10.1155/2011/840194

    PubMed

    researchmap

  • Involvement of peripheral mu opioid receptors in scratching behavior in mice. Reviewed International journal

    Atsuki Yamamoto, Yukio Sugimoto

    European journal of pharmacology   649 ( 1-3 )   336 - 41   2010.12

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Pruritus is a common adverse effect of opioid treatment. However, the mechanism by which pruritus is induced by opioid administration is unclear. In this study, we examined the effects of the intradermal injection of loperamide, a peripherally restricted opioid receptor agonist, on the itch sensation. When injected intradermally into the rostral part of the back in mice, loperamide elicited scratching behavior. We also examined the effects of the selective mu opioid receptor agonist [d-Ala², N-Me-Phe⁴, Gly⁵-ol]-enkephalin acetate (DAMGO), the selective delta opioid receptor agonist [d-Pen(2,5)]-enkephalin (DPDPE), and the selective kappa opioid receptor agonist U-50488H on scratching behavior in mice in order to determine which subtype is involved in opioid-induced pruritus. Following intradermal injection into the rostral part of the back in mice, DAMGO elicited scratching behavior, while DPDPE and U-50488H did not. This suggests that peripheral mu opioid activation elicits the itch sensation. Next, we focused on the treatment of opioid-induced itch sensation without central adverse effects. Naloxone methiodide is a peripherally restricted opioid receptor antagonist. In the present study, naloxone methiodide significantly suppressed scratching behavior induced by loperamide and DAMGO. These findings suggest that mu opioid receptors play a primary role in peripheral pruritus and that naloxone methiodide may represent a possible remedy for opioid-induced itching.

    DOI： 10.1016/j.ejphar.2010.07.039

    PubMed

    researchmap

  • Effect of 5-aminosalicylate on allergic rhinitis model in mice. Reviewed International journal

    Shoji Kuyama, Atsuki Yamamoto, Mayu Sugiyama, Hiroki Kakuta, Yukio Sugimoto

    International immunopharmacology   10 ( 6 )   713 - 6   2010.6

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Previous studies have shown that peroxisome proliferator-activated receptor gamma (PPARgamma) is involved in allergic rhinitis. It has been reported that 5-aminosalicylate (5-ASA) has an affinity for PPARgamma, but the effects of 5-ASA on the nasal symptoms of allergic rhinitis are unclear. This study aimed to clarify the effects of 5-ASA on nasal symptoms in an allergic rhinitis model in mice. Female BALB/c mice were sensitized by intraperitoneal injection of ovalbumin (OVA) and aluminium hydroxide hydrate gel (alum) on days 0, 5, 14 and 21. Seven days later, mice were sensitized by the intranasal application of OVA thrice a week. 5-ASA was also administered orally after instillation of the antigen from day 28. The severity of allergic rhinitis was assessed by determining the extent of 2 nasal allergic symptoms-sneezing and nasal rubbing. In addition, serum OVA-specific immunoglobulin E (IgE) antibody, interleukin (IL)-4, and IL-10 levels in nasal lavage fluid and histamine sensitivity were determined. Repeated oral administration of 5-ASA attenuated the progression of nasal symptoms in sensitized mice in a dose-dependent manner. Additionally, 5-ASA prevented an increase in histamine sensitivity. Finally, 5-ASA inhibited both OVA-specific IgE antibody and IL-4 production; however, it had no effect on IL-10 levels. These results indicate that 5-ASA has a prophylactic effect on allergic rhinitis.

    DOI： 10.1016/j.intimp.2010.03.007

    PubMed

    researchmap

  • Characterization of scratching behavior induced by intradermal administration of morphine and fentanyl in mice. Reviewed International journal

    Atsuki Yamamoto, Shoji Kuyama, Chiaki Kamei, Yukio Sugimoto

    European journal of pharmacology   627 ( 1-3 )   162 - 6   2010.2

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Itching is known as a commonly side effect of opioid administration. However, the relationship of opioid receptors to itching is unclear. In this study, we examined the effect of intradermal injection of morphine and fentanyl on the itching sensation. When injected intradermally into the rostral back of mice, morphine and fentanyl elicited scratching behavior. In addition, an opioid receptor antagonist, naloxone, and a peripherally restricted opioid receptor antagonist, naloxone methiodide, significantly suppressed morphine- and fentanyl-induced scratching behavior. Moreover, the morphine-induced scratching behavior was suppressed by histamine H(1) receptor antagonists, such as diphenhydramine, chlorpheniramine, epinastine and cetirizine. On the other hand, fentanyl-induced scratching behavior was not suppressed by histamine H(1) receptor antagonists. Additionally, scratching behavior induced by morphine and fentanyl were not suppressed by glucocorticoids (predonisolone and dexamethasone). In conclusion, opioid-induced itching may involve in peripheral opioid receptors. Moreover, histamine and arachidonic acid metabolites played no main role in opioid-induced scratching behavior.

    DOI： 10.1016/j.ejphar.2009.10.066

    PubMed

    researchmap

  • Effect of the oral absorption of benzenesulfonanilide-type cyclooxygenase-1 inhibitors on analgesic action and gastric ulcer formation. Reviewed International journal

    Xiaoxia Zheng, Hiroyuki Oda, Shun Harada, Yukio Sugimoto, Akihiro Tai, Kenji Sasaki, Hiroki Kakuta

    Journal of pharmaceutical sciences   97 ( 12 )   5446 - 52   2008.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A benzensulfonanilide-type cyclooxygenase-1 (COX-1)-selective inhibitor, ZXX2-77: 4-amino-4'-chloro-N-methylbenzenesulfonanilide (4a), has been reported as a novel analgesic that does not cause gastric damage. This compound has a weak analgesic effect but has potent in vitro COX-1 inhibitory activity. Since the reason for the weak analgesic effect in vivo was thought to be the low rate of oral absorption, the blood concentration of ZXX2-77 (4a) was measured in rats. It was found that the C(max) value (1.2 microM) of ZXX2-77 (4a) at a dose of 30 mg/kg did not reach the COX-1 IC(50) value (3.2 microM). On the other hand, ZXX2-79 (4b) (SO(2)NH derivative of ZXX2-77 (4a); 4-amino-4'-chlorobenzenesulfonanilide), which shows less potent COX inhibitory activities (COX-1 IC(50) = 12 microM, COX-2 IC(50) = 150 microM) than those of ZXX2-77 (4a) in vitro, was found to be more absorbable (C(max) = 16 microM at a dose of 30 mg/kg in rats) than ZXX2-77 (4a). Furthermore, ZXX2-79 (4b) not only showed a potent analgesic effect in a formalin test but also caused little gastric damage. These findings indicate that demethylated sulfonamide compounds are more easily absorbed than are N-methylated sulfonamide compounds and suggest that COX-1-selective inhibitors will be useful as analgesics that do not cause gastric damage.

    DOI： 10.1002/jps.21388

    PubMed

    researchmap

  • Participation of histamine H3 receptors in experimental allergic rhinitis of mice. Reviewed

    Emiko Yokota, Shoji Kuyama, Yukio Sugimoto, Masami Ogawa, Chiaki Kamei

    Journal of pharmacological sciences   108 ( 2 )   206 - 11   2008.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The present study was performed to study the participation of histamine H(3) receptors in nasal symptoms using Sch 50971, a potent and selective agonist of the H(3) receptor. Repeated topical application of antigen caused an increase in sneezing and nasal rubbing in sensitized mice. Oral administration of Sch 50971 and imetit, specific H(3)-receptor agonists, resulted in an inhibition of nasal symptoms induced by an antigen similar to an H(1)-receptor antagonist, cetirizine. Furthermore, simultaneous use of H(3)-receptor agonists, Sch 50971 or imetit, and an H(1)-receptor antagonist, cetirizine, caused a significant inhibitory effect on nasal symptoms at doses that showed no effect when used separately. The number of eosinophils in the nasal mucosa of mice sensitized with antigen was significantly decreased by cetirizine; however, Sch 50971 and imetit had no effect on eosinophil infiltration. These results clearly indicate that H(3) receptors are involved in the etiology of nasal allergy, and the stimulation of H(3) receptors may be useful as a novel therapeutic approach in nasal allergy.

    PubMed

    researchmap

  • Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. Reviewed International journal

    Hiroki Kakuta, Xiaoxia Zheng, Hiroyuki Oda, Shun Harada, Yukio Sugimoto, Kenji Sasaki, Akihiro Tai

    Journal of medicinal chemistry   51 ( 8 )   2400 - 11   2008.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide ( 18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 +/- 0.05 microM, COX-2 IC 50 = 210 +/- 10 microM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.

    DOI： 10.1021/jm701191z

    PubMed

    researchmap

  • Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors (vol 15, pg 1014, 2007) Reviewed

    Zheng Xiaoxia, Oda Hiroyuki, Takamatsu Kayo, Sugimoto Yukio, Tai Akihiro, Akaho Eiichi, Ali Hamed Ismail, Oshiki Toshiyuki, Kakuta Hiroki, Sasaki Kenji

    BIOORGANIC & MEDICINAL CHEMISTRY   15 ( 9 )   3299 - 3300   2007.5

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bmc.2007.01.059

    Web of Science

    Scopus

    researchmap

  • Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Reviewed International journal

    Xiaoxia Zheng, Hiroyuki Oda, Kayo Takamatsu, Yukio Sugimoto, Akihiro Tai, Eiichi Akaho, Hamed Ismail Ali, Toshiyuki Oshiki, Hiroki Kakuta, Kenji Sasaki

    Bioorganic & medicinal chemistry   15 ( 2 )   1014 - 21   2007.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    In order to create novel analgesic agents without gastric disturbance, structurally simple cyclooxygenase-1 (COX-1) inhibitors with a benzenesulfonanilide skeleton were designed and synthesized. As a result, compounds 11f and 15a, which possess a p-amino group on the benzenesulfonyl moiety and p-chloro group on the anilino moiety, showed COX-1-selective inhibition. Moreover compound 11f, which is the most potent compound in this study showed more potent analgesic activity than that of aspirin at 30 mg/kg by po. The anti-inflammatory activity and gastric damage, however, were very weak or not detectably different from aspirin. Since the structure of our COX-1 inhibitors are very simple, they may be useful as lead compounds for superior COX-1 inhibitors as analgesic agents without gastric disturbance.

    PubMed

    researchmap

  • Histamine H<inf>3</inf> receptors regulate vascular permeability changes in the skin of mast cell-deficient mice Reviewed

    Maria Alejandra Hossen, Yoko Fujii, Yukio Sugimoto, Ryoji Kayasuga, Chiaki Kamei

    International Immunopharmacology   3 ( 12 )   1563 - 1568   2003.11

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S1567-5769(03)00009-2

    Scopus

    PubMed

    researchmap

  • Histamine H3 receptors regulate vascular permeability changes in the skin of mast cell-deficient mice. Reviewed International journal

    Maria Alejandra Hossen, Yoko Fujii, Yukio Sugimoto, Ryoji Kayasuga, Chiaki Kamei

    International immunopharmacology   3 ( 12 )   1563 - 8   2003.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The participation of histamine H(3) receptors in the regulation of skin vascular permeability changes in mast cell-deficient mice was studied. Although intradermal injection of histamine H(3) antagonists, iodophenpropit and clobenpropit, at a dose of 100 nmol/site caused significant increases in skin vascular permeability in both mast cell-deficient (WBB6F1 W/W(v)) and wild-type (WBB6F1 +/+) mice, this response was significantly lower in mast cell-deficient mice than in the wild-type controls. Histamine also caused dose-related increases in skin vascular permeability in both wild-type and mast cell-deficient mice. Significant effects were observed at doses of 10 and 100 nmol/site, and no significant difference in skin vascular permeability was observed between mast cell-deficient and wild-type mice. However, histamine contents of dorsal skin in mast cell-deficient mice were significantly lower than in wild-type mice. In addition, the H(1) antagonists diphenhydramine and chlorpheniramine and the NK(1) antagonists, L-732,138 and L-733,060, were able to antagonize H(3) antagonist-induced skin vascular permeability. These results indicated that blockade of H(3) receptors by H(3) antagonists induce skin vascular permeability through mast cell-dependent mechanisms. In addition, histamine and, to a lesser extent substance P are involved in the reaction.

    PubMed

    researchmap

  • Inhibitory effects of glucocorticoids on rat eosinophil superoxide generation and chemotaxis Reviewed

    Yukio Sugimoto, Masami Ogawa, Nobuyuki Tai, Chiaki Kamei

    International Immunopharmacology   3 ( 6 )   845 - 852   2003.6

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S1567-5769(03)00055-9

    Scopus

    PubMed

    researchmap

  • Inhibitory effects of glucocorticoids on rat eosinophil superoxide generation and chemotaxis. Reviewed International journal

    Yukio Sugimoto, Masami Ogawa, Nobuyuki Tai, Chiaki Kamei

    International immunopharmacology   3 ( 6 )   845 - 52   2003.6

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    Eosinophil infiltration into inflammatory tissues and the subsequent release of inflammatory mediators are the hallmarks of several inflammatory allergic diseases. Although there have been a considerable number of publications on anti-inflammatory effects of glucocorticoids, little is known about whether glucocorticoids affect the activation of eosinophils directly. We studied the effects of three glucocorticoids, mometasone furoate, dexamethasone and beclomethasone dipropionate, on superoxide generation and the chemotaxis of rat eosinophils. Highly purified rat eosinophils were treated for 6 h with mometasone furoate, dexamethasone or beclomethasone dipropionate. Eosinophils were stimulated with phorbol myristate acetate (PMA) for superoxide generation, while for induction of chemotaxis, platelet-activating factor (PAF) or leukotriene B(4) (LTB(4)) was used. None of the glucocorticoids used in the present study caused significant suppressive effects on superoxide generation induced by PMA. On the other hand, both PAF- and LTB(4)-induced migration of rat eosinophils were inhibited in a concentration-dependent manner by glucocorticoids. Mometasone furoate showed a significant effect at concentrations higher than 10(-11) M. Dexamethasone and beclomethasone dipropionate also caused a significant inhibition at concentrations higher than 10(-8) and 10(-7) M, respectively. These results indicated that the anti-inflammatory effects of glucocorticoids were mediated by direct inhibition of eosinophil migration. Furthermore, mometasone furoate was suggested to be more useful than the other drugs in the treatment of allergic diseases responsible for eosinophil chemotaxis.

    PubMed

    researchmap

  • Evaluation of the effects of anti-pruritic drugs on scratch responses using histamine H1 receptor-deficient mice. Reviewed International journal

    Yukio Sugimoto, Yosuke Nakamura, Maria Alejandra Hossen, Takeshi Watanabe, Chiaki Kamei

    European journal of pharmacology   470 ( 1-2 )   113 - 6   2003.5

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    The effects of anti-pruritic drugs on scratching behavior associated with passive cutaneous anaphylaxis in histamine H(1) receptor-deficient and wild-type mice were studied. Passive sensitization with mouse monoclonal anti-dinitrophenyl-immunoglobulin E (IgE) resulted in an increase in the incidence of scratching behavior induced by intravenous injection of dinitrophenyl-ovalbumin in both wild-type and histamine H(1) receptor-deficient mice. The histamine H(1) receptor antagonist diphenhydramine inhibited scratching behavior induced by antigen in passively sensitized wild-type mice, whereas no effect was observed in histamine H(1) receptor-deficient mice. On the other hand, oxatomide inhibited scratching behavior in both mice, although the effect in wild-type mice was more potent than that in histamine H(1) receptor-deficient mice. Tranilast inhibited scratching behavior with the same potency in both mice. We concluded that the scratching behavior associated with passive cutaneous anaphylaxis involves not only histamine H(1) receptors but also other chemical mediators. Furthermore, the results of the present study indicated that oxatomide has an antagonistic effect on histamine H(1) receptors as well as anti-pruritic effect in vivo.

    PubMed

    researchmap

  • Inhibitory effects of propolis granular A P C on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Reviewed International journal

    Yukio Sugimoto, Yoshinori Iba, Ryoji Kayasuga, Yasushi Kirino, Miyuki Nishiga, Maria Alejandra Hossen, Kiyoshi Okihara, Hiroyuki Sugimoto, Hideo Yamada, Chiaki Kamei

    Cancer letters   193 ( 2 )   155 - 9   2003.4

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    We examined the effect of propolis granular A. P. C on lung tumorigenesis in female A/J mice. Lung tumors were induced by the tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) administered in drinking water for 7 weeks in mice maintained on an AIN-76A semi-synthetic diet. Propolis granular A. P. C (100 mg/kg body wt.) was administered orally daily for 6 days/week from 1 week before NNK administration and throughout the experiment. Sixteen weeks after the NNK treatment, the mice were killed and the number of surface lung tumors was measured. The number of lung tumors in mice treated with NNK alone for 7 weeks (9.4 mg/mouse) was significantly more than in that observed in control mice. Propolis granular A. P. C significantly decreased the number of lung tumors induced by NNK. These results indicate that propolis granular A. P. C is effective in suppressing NNK-induced lung tumorigenesis in mice.

    PubMed

    researchmap

  • Possible role of mucosal mast cells in the recovery process of colitis induced by dextran sulfate sodium in rats Reviewed

    Yoshinori Iba, Yukio Sugimoto, Chiaki Kamei, Tohru Masukawa

    International Immunopharmacology   3 ( 4 )   485 - 491   2003.4

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S1567-5769(02)00299-0

    Scopus

    PubMed

    researchmap

  • Inhibitory effects of propolis granular A. P. C on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice Reviewed

    Yukio Sugimoto, Yoshinori Iba, Ryoji Kayasuga, Yasushi Kirino, Miyuki Nishiga, Maria Alejandra Hossen, Kiyoshi Okihara, Hiroyuki Sugimoto, Hideo Yamada, Chiaki Kamei

    Cancer Letters   193 ( 2 )   155 - 159   2003.4

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0304-3835(03)00016-8

    Scopus

    PubMed

    researchmap

  • Effects of [Arg8]-vasopressin on regional cerebral blood flow in spontaneously hypertensive rats Reviewed

    N. Azuma, Y. Sugimoto, M. Mio, K. Shinomiya, Chiaki Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   25 ( 3 )   193 - 197   2003.4

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1358/mf.2003.25.3.769639

    Scopus

    PubMed

    researchmap

  • Effects of NMDA antagonist MK-801 on radial maze performance in Zucker rats. Reviewed International journal

    Miyuki Nishiga, Yoko Fujii, Yukio Sugimoto, Masako Konishi, Chiaki Kamei

    Brain research   950 ( 1-2 )   127 - 9   2002.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We examined the participation of the NMDA receptor in the histaminergic system using radial maze performance in Zucker rats. Although pyrilamine caused a significant effect on spatial memory deficit in lean rats, no significant spatial memory deficit was observed in obese rats. On the other hand, MK-801 caused significant spatial memory deficits in obese rats in comparison with lean rats. These results indicate that the histaminergic neuron is not closely related with the radial maze performance in obese rats. In addition, the potent effect of MK-801 observed in obese rats compared with lean rats may be responsible for the activation of NMDA receptors in obese rats.

    PubMed

    researchmap

  • Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors. Reviewed International journal

    Ryoji Kayasuga, Yukio Sugimoto, Takeshi Watanabe, Chiaki Kamei

    European journal of pharmacology   449 ( 3 )   287 - 91   2002.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The purpose of this study was to investigate the involvement of chemical mediators other than histamine in nasal allergic signs using histamine H(1) receptor-deficient mice. In passively sensitized mice, antigen instillation into the nasal cavity induced significant increases in sneezing and nasal rubbing in wild-type mice, but no such increases were observed in histamine H(1) receptor-deficient mice. In actively sensitized mice, both sneezing and nasal rubbing were also significantly increased in a dose-dependent manner in both wild-type and histamine H(1) receptor-deficient mice. Histamine H(1) receptor antagonists such as cetirizine and epinastine significantly inhibited antigen-induced nasal allergic signs in wild-type mice, although the effects were incomplete. In addition, the thromboxane A(2) receptor antagonist ramatroban also inhibited these responses in wild-type mice. However, the leukotriene receptor antagonist zafirlukast showed no effects in wild-type mice. These results suggested that in the acute allergic model (passive sensitization), only histamine H(1) receptors are related to nasal signs induced by antigen, whereas in the chronic allergic model (active sensitization), both histamine H(1) receptors and thromboxane A(2) receptors were involved in the responses.

    PubMed

    researchmap

  • Effect of docosahexaenoic acid-fortified Chlorella vulgaris strain CK22 on the radial maze performance in aged mice Reviewed

    Yukio Sugimoto, Chiyomi Taga, Miyuki Nishiga, Madoka Fujiwara, Fumiko Konishi, Kuniaki Tanaka, Chiaki Kamei

    Biological and Pharmaceutical Bulletin   25 ( 8 )   1090 - 1092   2002.8

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.25.1090

    Scopus

    PubMed

    researchmap

  • Histamine H1 receptors are involved in mouse nasal allergic responses: a demonstration with H1 receptor-deficient mice. Reviewed International journal

    Ryoji Kayasuga, Yukio Sugimoto, Takeshi Watanabe, Chiaki Kamei

    International immunopharmacology   2 ( 6 )   745 - 50   2002.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The role of histamine H1 receptors in nasal allergic symptoms (sneezing and nasal rubbing) were studied using histamine H1 receptor-deficient mice. Intranasal instillation of histamine solution resulted in significant increases in sneezing and nasal rubbing in wild-type mice, whereas no increases were observed in histamine H1 receptor-deficient mice. The histamine H1 receptor agonist 2-pyridylethylamine induced sneezing and nasal rubbing in a dose-dependent-manner in wild-type mice, but no such increase was found in histamine H1 receptor-deficient mice. On the other hand, the histamine H2 receptor agonist dimaprit did not increase sneezing and nasal rubbing in wild-type mice. Histamine H1 receptor antagonists such as chlorpheniramine and epinastine significantly inhibited nasal allergic symptoms caused by histamine, but the histamine H2 receptor antagonists cimetidine and famotidine showed no effect. No additional effects were observed by combined use of chlorpheniramine and cimetidine or famotidine compared with cimetidine or famotidine alone. These results suggested that histamine H1 receptors play an important role in nasal allergy symptoms induced by histamine.

    PubMed

    researchmap

  • Effects of the NMDA antagonist MK-801 on radial maze performance in histidine-deficient rats. Reviewed International journal

    Miyuki Nishiga, Yukio Sugimoto, Chiyomi Taga, Yoko Fujii, Chiaki Kamei

    Life sciences   70 ( 18 )   2199 - 208   2002.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We examined the effects of a histidine-deficient diet on brain histamine contents as well as on learning and memory using the eight-arm radial maze in rats. A significant decrease in histamine content in the hippocampus was observed after long-term feeding of rats with a histidine-deficient diet. At the same time, significant enhancement of the acquisition process in radial maze performance was also observed. Pyrilamine did not show a significant effect on radial maze performance in histidine-deficient rats. On the other hand, pyrilamine caused a significant spatial memory deficit in control rats. Scopolamine was effective in inhibiting spatial memory in both histidine-deficient and control rats. MK-801 caused spatial memory deficits more potently in histidine-deficient rats than in controls. Brain glycine contents showed a significant increase in the hippocampus in histidine-deficient rats. These results indicated that the spatial memory deficits induced by MK-801 in histidine-deficient rats are closely related to increased glycine levels and activation of NMDA receptors.

    PubMed

    researchmap

  • Antiallergic effect of flavonoid glycosides obtained from Mentha piperita L. Reviewed

    Toshio Inoue, Yukio Sugimoto, Hideki Masuda, Chiaki Kamei

    Biological & pharmaceutical bulletin   25 ( 2 )   256 - 9   2002.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Six flavonoid glycosides, eriocitrin (1), narirutin (2), hesperidin (3), luteolin-7-O-rutinoside (4), isorhoifolin (5), diosmin (6), rosmarinic acid (7) and 5,7-dihydroxycromone-7-O-rutinoside (8), were isolated from the aerial part of Mentha piperita L. Among these compounds, compound 4 showed a potent inhibitory effect on histamine release induced by compound 48/80 and antigen-antibody reaction. This compound was more effective than luteolin and luteolin-7-O-glucoside in inhibiting histamine release from rat peritoneal mast cells. Compound 4 also caused a dose-related inhibition of the antigen-induced nasal response and significant effects were observed at doses of 100 and 300 mg/kg. These results indicate that compound 4 may be clinically useful in alleviating the nasal symptoms of allergic rhinitis.

    PubMed

    researchmap

  • Participation of mast cells in colitis inflammation induced by dextran sulfate sodium Reviewed

    Y. Iba, Y. Sugimoto, C. Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   24 ( 1 )   15 - 18   2002

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1358/mf.2002.24.1.677122

    Scopus

    PubMed

    researchmap

  • Changes in membrane potential induced by compound 48/80 in the peritoneal mast cells of rats Reviewed

    Y. Nakayama, M. Mio, Y. Sugimoto, Y. Fujii, Chiaki Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   24 ( 5 )   267 - 273   2002

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1358/mf.2002.24.5.802303

    Scopus

    PubMed

    researchmap

  • Histamine H<inf>1</inf> receptors are involved in mouse nasal allergic responses: A demonstration with H<inf>1</inf> receptor-deficient mice Reviewed

    Ryoji Kayasuga, Yukio Sugimoto, Takeshi Watanabe, Chiaki Kamei

    International Immunopharmacology   2 ( 6 )   745 - 750   2002

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S1567-5769(02)00010-3

    Scopus

    PubMed

    researchmap

  • Effects of vasopressin on histamine H<inf>1</inf> receptor antagonist-induced spatial memory deficits in rats Reviewed

    Chiyomi Taga, Yukio Sugimoto, Miyuki Nishiga, Yoko Fujii, Chiaki Kamei

    European Journal of Pharmacology   423 ( 2-3 )   167 - 170   2001.7

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0014-2999(01)01080-9

    Scopus

    PubMed

    researchmap

  • Effects of peppermint (Mentha piperita L.) extracts on experimental allergic rhinitis in rats Reviewed

    Toshio Inoue, Yukio Sugimoto, Hideki Masuda, Chiaki Kamei

    Biological and Pharmaceutical Bulletin   24 ( 1 )   92 - 95   2001

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.24.92

    Scopus

    PubMed

    researchmap

  • Effects of histidine on working memory deficits induced by the 5-HT<inf>1A</inf>-receptor agonist 8-OH-DPAT Reviewed

    S. Isayama, Y. Sugimoto, M. Nishiga, C. Kamei

    Japanese Journal of Pharmacology   86 ( 4 )   451 - 453   2001

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1254/jjp.86.451

    Scopus

    PubMed

    researchmap

  • Involvement of mast cells in inflammation sites of colitis induced by dextran sulfate sodium Reviewed

    Y Iba, Y Sugimoto, C Kamei

    HISTAMINE RESEARCH IN THE NEW MILLENNIUM   1224   439 - 440   2001

    　More details

    Language：English   Publishing type：Research paper (international conference proceedings)  

    Web of Science

    researchmap

  • The role of endogenous histamine in learning and memory in rats Reviewed

    C Kamei, Y Sugimoto, Z Chen

    HISTAMINE RESEARCH IN THE NEW MILLENNIUM   1224   461 - 462   2001

    　More details

    Language：English   Publishing type：Research paper (international conference proceedings)  

    Web of Science

    researchmap

  • Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats Reviewed

    Chiaki Kamei, Masaya Ohuchi, Yukio Sugimoto, Chihiro Okuma

    Brain Research   887 ( 1 )   183 - 186   2000.12

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0006-8993(00)03041-9

    Scopus

    PubMed

    researchmap

  • Vascular permeability in allergic conjunctivitis in mice lacking histamine H<inf>1</inf> receptors Reviewed

    Hiroto Nakahara, Keiji Izushi, Yukio Sugimoto, Takeshi Watanabe, Chiaki Kamei

    European Journal of Pharmacology   409 ( 3 )   313 - 317   2000.12

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0014-2999(00)00863-3

    Scopus

    PubMed

    researchmap

  • Effect of mometasone furoate by topical application on allergic rhinitis model in rats Reviewed

    Yukio Sugimoto, Keisuke Ishizawa, Kouichi Saitou, Genzo Suzuki, Tadatsugu Tarumi, Hiroto Nakahara, Yasushi Kirino, Chiaki Kamei

    Pharmacology   61 ( 2 )   91 - 95   2000.8

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000028386

    Scopus

    PubMed

    researchmap

  • A new model of allergic rhinitis in rats by topical sensitization and evaluation of H<inf>1</inf>-receptor antagonists Reviewed

    Yukio Sugimoto, Etsuko Kawamoto, Zhong Chen, Chiaki Kamei

    Immunopharmacology   48 ( 1 )   1 - 7   2000.6

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0162-3109(00)00173-9

    Scopus

    PubMed

    researchmap

  • Experimental allergic conjunctivitis in guinea pigs induced by Japanese cedar pollen Reviewed

    Miho Takada, Tamao Yamada, Hiroto Nakahara, Yukio Sugimoto, Keiji Izushi, Chiaki Kamei

    Biological and Pharmaceutical Bulletin   23 ( 5 )   566 - 569   2000.5

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.23.566

    Scopus

    PubMed

    researchmap

  • Effects of metabolic fragments of [Arg8]-vasopressin on nerve growth in cultured hippocampal neurons Reviewed

    Tadatsugu Tarumi, Yukio Sugimoto, Zhong Chen, Qiue Zhao, Chiaki Kamei

    Brain Research Bulletin   51 ( 5 )   407 - 411   2000.4

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0361-9230(99)00249-X

    Scopus

    PubMed

    researchmap

  • The mechanism responsible for the drowsiness caused by first generation H<inf>1</inf> antagonists on the EEG pattern Reviewed

    Y. Kaneko, K. Shimada, K. Saitou, Y. Sugimoto, Chiaki Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   22 ( 3 )   163 - 168   2000

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Participation of GABAergic and histaminergic systems in inhibiting amygdaloid kindled seizures Reviewed

    Keisuke Ishizawa, Zhong Chen, Chihiro Okuma, Yukio Sugimoto, Yoko Fujii, Chiaki Kamei

    Japanese Journal of Pharmacology   82 ( 1 )   48 - 53   2000

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1254/jjp.82.48

    Scopus

    PubMed

    researchmap

  • Effects of Fujibitol, a remedy for nasal symptoms, on experimental allergic rhinitis in rats Reviewed

    M. Kakimoto, Y. Sugimoto, M. Harada, Y. Kobayashi, C. Okuma, C. Taga, C. Kamei

    Biological and Pharmaceutical Bulletin   23 ( 9 )   1055 - 1058   2000

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.23.1055

    Scopus

    PubMed

    researchmap

  • Influences of everninomicin, vancomycin and teicoplanin on chemical mediator release from rat peritoneal mast cells Reviewed

    Y. Sugimoto, Y. Iba, K. Utsugi, C. Kamei

    Japanese Journal of Pharmacology   83 ( 4 )   300 - 305   2000

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1254/jjp.83.300

    Scopus

    PubMed

    researchmap

  • Effect of propolis extract on D-galactosamine-induced hepatic injury in rats Reviewed

    Yukio Sugimoto, Tadatsugu Tarumi, Yoshio Kaneko, Shinji Isayama, Nobuyuki Kawai, Hiroyuki Sugimoto, Hideo Yamada, Chiaki Kamei

    Biological and Pharmaceutical Bulletin   22 ( 11 )   1237 - 1239   1999.11

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.22.1237

    Scopus

    PubMed

    researchmap

  • Effects of intracerebroventricular injection of α-fluoromethylhistidine on radial maze performance in rats Reviewed

    Zhong Chen, Yukio Sugimoto, Chiaki Kamei

    Pharmacology Biochemistry and Behavior   64 ( 3 )   513 - 518   1999.11

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0091-3057(99)00128-8

    Scopus

    PubMed

    researchmap

  • Slow wave sleep-inducing effects of first generation H<inf>1</inf>-antagonists Reviewed

    Koichi Saitou, Yoshio Kaneko, Yukio Sugimoto, Zhong Chen, Chiaki Kamei

    Biological and Pharmaceutical Bulletin   22 ( 10 )   1079 - 1082   1999.10

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.22.1079

    Scopus

    PubMed

    researchmap

  • Effects of histamine on MK-801-induced memory deficits in radial maze performance in rats Reviewed

    Zhong Chen, Quie Zhao, Yukio Sugimoto, Yoko Fujii, Chiaki Kamei

    Brain Research   839 ( 1 )   186 - 189   1999.8

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0006-8993(99)01739-4

    Scopus

    PubMed

    researchmap

  • [Arg8]-vasopressin-induced increase in intracellular Ca2+ concentration in cultured rat hippocampal neurons Reviewed

    Takuma Mihara, Tadatsugu Tarumi, Yukio Sugimoto, Zhong Chen, Chiaki Kamei

    Brain Research Bulletin   49 ( 5 )   343 - 347   1999.7

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0361-9230(99)00064-7

    Scopus

    PubMed

    researchmap

  • Effects of fujibitol, a remedy for nasal symptoms of immediate and delayed type allergic reactions Reviewed

    Masanori Kakimoto, Naoyuki Takasugi, Tohru Fuwa, Hiroshi Saito, Yukio Sugimoto, Chiaki Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   21 ( 5 )   353 - 356   1999

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1358/mf.1999.21.5.541913

    Scopus

    PubMed

    researchmap

  • Effects of levocabastine on lipid mediator release from guinea pig lung fragments Reviewed

    Yukio Sugimoto, Yoshinori Iba, Keisuke Ishizawa, Genzo Suzuki, Chiaki Kamei

    Acta Medica Okayama   53 ( 6 )   271 - 274   1999

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Studies on the sleep-inducing effect of diphenhydramine hydrochloride

    Chiaki Kamei, Koichi Saito, Yukio Sugimoto, Zhong Chen, Qiue Zhao

    Japanese Pharmacology and Therapeutics   27 ( 5 )   18 - 19   1999

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    researchmap

  • Effects of histamine and related compounds on regional cerebral blood flow in rats Reviewed

    G. Suzuki, Z. Chen, Y. Sugimoto, Y. Fujii, C. Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   21 ( 9 )   613 - 617   1999

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effects of anti-Parkinsonian drugs on neurobehavioural changes induced by bilateral 6-hydroxydopamine lesions in rats Reviewed

    T. Hayakawa, Y. Sugimoto, Z. Chen, Y. Fujii, C. Kamei

    Clinical and Experimental Pharmacology and Physiology   26 ( 5-6 )   421 - 425   1999

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1046/j.1440-1681.1999.03051.x

    Scopus

    PubMed

    researchmap

  • 432 ペパーミント抽出物のラット抗原誘発鼻アレルギーデルに対する効果 Reviewed

    井上 俊夫, 杉本 幸雄, 亀井 千晃

    アレルギー   48 ( 8 )   1052 - 1052   1999

    　More details

    Language：Japanese   Publisher：一般社団法人 日本アレルギー学会  

    DOI： 10.15036/arerugi.48.1052_4

    CiNii Article

    researchmap

  • Strain differences in histamine release from peritoneal mast cells in rats Reviewed

    Y. Sugimoto, H. Ohishi, T. Toyota, C. Kamei

    General Pharmacology   31 ( 4 )   613 - 616   1998.10

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0306-3623(98)00063-9

    Scopus

    PubMed

    researchmap

  • Effects of antiallergic drugs on histamine release from rat peritoneal mast cells induced by bradykinin Reviewed

    Y. Sugimoto, T. Tarumi, Q. E. Zhao, Y. Fujii, C. Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   20 ( 6 )   457 - 462   1998.7

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1358/mf.1998.20.6.485708

    Scopus

    PubMed

    researchmap

  • Effects of histamine H<inf>1</inf> receptor antagonists on compound 48/80-induced scratching behavior in mice Reviewed

    Yukio Sugimoto, Keiko Umakoshi, Nao Nojiri, Chiaki Kamei

    European Journal of Pharmacology   351 ( 1 )   1 - 5   1998.6

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S0014-2999(98)00288-X

    Scopus

    PubMed

    researchmap

  • Effects of apafant on PAF-induced downregulation of β-adrenoceptors in guinea pigs Reviewed

    Y. Sugimoto, Y. Nakayama, H. Kishida, T. Hayakawa, R. Fujiwara, C. Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   19 ( 8 )   547 - 552   1997

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effects of intracerebroventricular injection of histamine on memory deficits induced by hippocampal lesions in rats Reviewed

    Chiaki Kamei, Zhong Chen, Satoru Nakamura, Yukio Sugimoto

    Methods and Findings in Experimental and Clinical Pharmacology   19 ( 4 )   253 - 259   1997

    　More details

    Authorship：Last author   Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effects of histamine and its related compounds on impairment of passive avoidance response following hippocampal lesions in rats Reviewed

    Z. Chen, Y. Sugimoto, C. Kamei

    Journal of Brain Science   23 ( 2-3 )   225 - 240   1997

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    researchmap

  • Effect of apafant on bronchial hyperresponsiveness and down-regulation of β-adrenoceptors induced by endotoxin in guinea pigs Reviewed

    Yukio Sugimoto, Takuma Mihara, Tsuyoshi Hayakawa, Yukinobu Nakayama, Hisako Kishida, Chiaki Kamei

    Arzneimittel-Forschung/Drug Research   47 ( 7 )   837 - 841   1997

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Role of substance P in experimental allergic conjunctivitis in guinea pigs Reviewed

    Masako Yamaji, Miho Takada, Rie Fujiwara, Hiroko Ohishi, Keiji Izushi, Yukio Sugimoto, Chiaki Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   19 ( 9 )   637 - 643   1997

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Mechanism of bradykinin-induced histamine release from rat peritoneal mast cells Reviewed

    Qiu E. Zhao, Takuma Mihara, Yukio Sugimoto, Chiaki Kamei

    Biological and Pharmaceutical Bulletin   19 ( 2 )   237 - 240   1996.2

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.19.237

    Scopus

    PubMed

    researchmap

  • Effects of histamine and related compounds on the bovine iris dilator Reviewed

    Chiaki Kamei, Yukio Sugimoto, Yasushi Okumura

    Methods and Findings in Experimental and Clinical Pharmacology   18 ( 4 )   273 - 278   1996

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effect of loratadine on histamine release induced by antigen-antibody reaction Reviewed

    Chiaki Kamei, Yukio Sugimoto, Masako Yamaji, Miho Takada

    Japanese Pharmacology and Therapeutics   24 ( 1 )   49 - 52   1996

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    researchmap

  • Epileptogenic activity induced by combined treatment with antiinflammatory drugs and enoxacin and its inhibition by a calcium antagonist, nicardipine Reviewed

    Chiaki Kamei, Yukio Sugimoto, Hiroko Ohishi, Yasushi Okumura, Kazuhiro Kitazumi

    Methods and Findings in Experimental and Clinical Pharmacology   18 ( 9 )   579 - 588   1996

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effect of mometasone furoate on experimental allergic rhinitis in rats Reviewed

    C. Kamei, Y. Sugimoto, H. Kakinoki, T. Izumo, C. Ichiki

    Japanese Pharmacology and Therapeutics   23 ( 11 )   109 - 112   1995

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    researchmap

  • Effect of (Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2- acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs Reviewed

    C. Kamei, Y. Sugimoto, S. Nakamura, C. Zhong

    Arzneimittel-Forschung/Drug Research   45 ( 9 )   1005 - 1008   1995

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effects of intracerebroventricular injection of histamine and its related compounds on rectal temperature in mice Reviewed

    Z. Chen, Y. Sugimoto, C. Kamei

    Methods and Findings in Experimental and Clinical Pharmacology   17 ( 10 )   669 - 675   1995

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • 62 モルモットの実験的結膜炎の作成および抗アレルギー薬の効果に関する検討 Reviewed

    出石 啓治, 杉本 幸雄, 亀井 千晃

    アレルギー   44 ( 8 )   914 - 914   1995

    　More details

    Language：Japanese   Publisher：一般社団法人 日本アレルギー学会  

    DOI： 10.15036/arerugi.44.914_2

    CiNii Article

    researchmap

  • The Role of Ions on Histamine-Induced Depolarization in Isolated Guinea Pig Adipocytes Reviewed

    Chiaki Kamei, Yukio Sugimoto

    The Japanese Journal of Pharmacology   66 ( 4 )   465 - 469   1994

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1254/jjp.66.465

    Scopus

    PubMed

    researchmap

  • Sequential analysis of histamine release and intracellular Ca2+ release from murine mast cells Reviewed

    Kenji Tasaka, Yukio Sugimoto, Mitsunobu Mio

    International Archives of Allergy and Immunology   91 ( 2 )   211 - 213   1990

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000235118

    Scopus

    PubMed

    researchmap

  • Influence of aging on the histamine release and membrane fluidity of rat peritoneal mast cells Reviewed

    M. Mio, H. Akahori, Y. Sugimoto, M. Akagi, K. Tasaka

    Pharmacology   38 ( 3 )   191 - 200   1989

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000138537

    Scopus

    PubMed

    researchmap

  • The antihypertensive effect of consecutive administration of nisoldipine in spontaneously hypertensive rats Reviewed

    K. Tasaka, C. Kamei, T. Hokonohara, Y. Sugimoto

    Japanese Pharmacology and Therapeutics   17 ( 4 )   417 - 423   1989

    　More details

    Publishing type：Research paper (scientific journal)  

    Scopus

    researchmap

  • The effects of cephem antibiotics and related compounds on the aldehyde dehydrogenase in rat liver mitochondria Reviewed

    Kamei Chiaki, Sugimoto Yukio, Tasaka Kenji

    Biochemical Pharmacology   36 ( 12 )   1933 - 1939   1987.6

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/0006-2952(87)90491-6

    Scopus

    PubMed

    researchmap

  • Antihypertensive effects of nisoldipine and reference drugs in certain types of hypertensive rats Reviewed

    K. Tasaka, C. Kamei, H. Tagami, T. Hokonohara, Y. Sugimoto

    Arzneimittel-Forschung/Drug Research   37 ( 3 )   316 - 321   1987

    　More details

    Authorship：Last author   Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Effects of various cephem antibiotics on ethanol metabolism and their structure‐activity relations Reviewed

    Chiaki Kamei, Yukio Sugimoto, Nobuaki Muroi, Kenji Tasaka

    Journal of Pharmacy and Pharmacology   38 ( 11 )   823 - 828   1986.11

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.2042-7158.1986.tb04502.x

    Scopus

    PubMed

    researchmap

▼display all

Books

  • FOOD STYLE 21

    杉本 幸雄（ Role： Contributor ,  特集 食品由来成分によるアレルギー対策）

    食品化学新聞社  2019.11 

    　More details

  • 小児科 特集 アレルギー疾患におけるステロイド薬の局所療法-作用メカニズムと使い方

    金原出版株式会社  2016 

    　More details

  • 肥満細胞の臨床

    先端医学社  2001 

    　More details

MISC

▼display all

Research Projects

  • ヒスタミンH1受容体欠損マウスを用いたアレルギー性鼻炎の解析

    Grant number：10771339  1998 - 1999

    日本学術振興会  科学研究費助成事業  奨励研究(A)

    杉本 幸雄

    　 More details

    Grant amount：\1600000 （ Direct expense: \1600000 ）

    アレルギー性鼻炎は血管透過性亢進反応および痒みを主体とした疾病であり,ヒスタミンが最も重妻な化学伝達物質であると考えられている.しかし,臨床において抗ヒスタミン薬のみでは十分な治療効果が認められないことからヒスタミン以外の因子の関与が想定されている.近年,アレルギー性鼻炎の発症および進展に神経ペプチドの関与を示唆する研究結果が報告されているが,神経ペプチドの鼻アレルギー症状発現における役割については未だ十分解明されていない.著者はこれまでにヒスタミンH1受容体欠損マウスにサブスタンスPを点鼻投与することにより有意なくしゃみ反応および鼻掻き行動が認められたことから,サブスタンスPはヒスタミンH1受容体を介さず鼻アレルギー症状を誘発させることを明らかにした.今回,ヒスタミンH1受容体欠損マウスを用いて鼻アレルギー症状発現におけるブラジキニンの影響について検討をおこなった.
    実験には,5-15週齢の雄性ヒスタミンH1受容体欠損マウスおよびその野生型マウスを用いた.マウスに種々な濃度のブラジキニン生理食塩溶液を点鼻投与し,誘発されるくしゃみ反応および鼻掻き行動の回数を測定することにより鼻アレルギー症状の指標とした.
    ヒスタミンH1受容体欠損マウスに0.1μg/2μlのブラジキニン生理食塩溶液を点鼻投与することによりくしゃみ反応および鼻掻き行動はほとんど観察されなかったが,1μg/2μl以上の濃度のブラジキニン生理食塩溶液を点鼻投与することにより有意なくしゃみ反応および鼻掻き行動が誘発された.
    以上の結果から,サブスタンスPのみならずブラジキニンもヒスタミンH1受容体を介さずに鼻アレルギー症状を誘発させることが明らかとなった.

    researchmap

  • Preparation of experimental allergic conjunctivitis model and effects of certain drugs

    Grant number：08672610  1996 - 1997

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    KAMEI Chiaki, SUGIMOTO Yukio

    　 More details

    Grant amount：\2000000 （ Direct expense: \2000000 ）

    The role of substance P in experimental allergic conjunctivitis induced by egg albumin was investigated with guinea pigs. Increase in vascular permeability of the conjunnctiva induced by antigen was significantly inhibited after repeated application of capsaicin. Substance P contents in the conjunctiva of guinea pig were decreased by topical instillation of antigen to the eyes, suggesting that substance P was released from the conjunctiva due to antigen-antibody reaction. Moreover, subconjunctival injection or topical application of substance P resulted in a dose-related conjunctivitis, and vascular permeability in the conjunctiva was also increased by substance P.In substance P-induced conjunctivitis, a significant edema was observed in the bulbar and palpebral conjunctiva, but no hyperemia was noted in all instances. Histamine contents of the conjunctiva and tears were not influenced by subconjunctival injection of substance P.However topical application of antigen and subconjunctival injection of compound 48/80 caused a significant decrease in hitamine contents, and that of tear was increased by both treatments. An increase in vascular permeability induced by antigen application was significantly inhibited by intravenous injection of FK888, which is a specific and potent NK-1 receptor antagonist. From these results, it is indicated that substance P is responsible for allergic conjunctivitis to some extent, and the conjunctival hyperpermeability induced by substance P is occurred through NK-1 receptor on the blood vessels, rather than by the direct action on the conjunctival mast cells during allergic conjunctival reactions. In addition, effects of certain drugs on substance P-induced conjunctivitis were investigated. H_1-antagonists such as ketotifen, chlorpheniramine and levocabastine caused a potent inhibitory effect, however, cromolyn sodium and tranilast showed no inhibitory effect on substance P-induced conjunctivitis even at high concentrations.

    researchmap

 

Class subject in charge

  • Introduction to Drug Research （2025academic year） Third semester  - 火3～4

  • Mechanism of human body and medical care （2025academic year） 1st semester  - 月7～8

  • Practice in Clinical and Biopharmaceutical Sciences （2025academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2025academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2025academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2025academic year） Third semester  - その他5～9

  • Practicals: Inflammatory Pharmacology （2025academic year） special  - その他

  • Research Projects: Inflammatory Pharmacology （2025academic year） special  - その他

  • Research Projects: Inflammatory Pharmacology （2025academic year） special  - その他

  • Advanced Lectures: Inflammatory Pharmacology （2025academic year） special  - その他

  • Inflammatory pharmacology （2025academic year） special  - その他

  • Inflammatory pharmacology （2025academic year） special  - その他

  • Life Science and Clinical Pharmaceutical Science （2025academic year） special  - その他

  • Life Science 3 （2025academic year） special  - その他

  • Physiology （2025academic year） 1st and 2nd semester  - 水5～6

  • Physiology （2025academic year） 1st and 2nd semester  - 水5～6

  • Physiology 1 （2025academic year） 1st semester  - 水5～6

  • Physiology 1 （2025academic year） 1st semester  - 水5～6

  • Physiology 2 （2025academic year） Second semester  - 水5～6

  • Physiology 2 （2025academic year） Second semester  - 水5～6

  • Pharmacology 7 （2025academic year） Third semester  - 金3～4

  • Pharmacology 7 （2025academic year） Third semester  - 金3～4

  • Pharmacology 8 （2025academic year） Fourth semester  - 金3～4

  • Pharmacology 8 （2025academic year） Fourth semester  - 金3～4

  • Pharmacology D （2025academic year） 3rd and 4th semester  - 金3～4

  • Pharmacology D （2025academic year） 3rd and 4th semester  - 金3～4

  • Small Group Discussion for Pharmaceutical Sciences （2025academic year） 1st semester  - 火3～4

  • Small Group Discussion for Pharmaceutical Sciences （2025academic year） 1st semester  - 火3～4

  • Introduction to Drug Research （2024academic year） Second semester  - 月3～4

  • Mechanism of human body and medical care （2024academic year） 1st semester  - 月3～4

  • Practice in Clinical and Biopharmaceutical Sciences （2024academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2024academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2024academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2024academic year） Third semester  - その他5～9

  • Practicals: Inflammatory Pharmacology （2024academic year） special  - その他

  • Research Projects: Inflammatory Pharmacology （2024academic year） special  - その他

  • Advanced Lectures: Inflammatory Pharmacology （2024academic year） special  - その他

  • Inflammatory pharmacology （2024academic year） special  - その他

  • Inflammatory pharmacology （2024academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2024academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2024academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2024academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2024academic year） special  - その他

  • Life Science and Clinical Pharmaceutical Science （2024academic year） special  - その他

  • Life Science 3 （2024academic year） special  - その他

  • Physiology （2024academic year） 1st and 2nd semester  - 水5～6

  • Physiology （2024academic year） 1st and 2nd semester  - 水5～6

  • Physiology 1 （2024academic year） 1st semester  - 水5～6

  • Physiology 1 （2024academic year） 1st semester  - 水5～6

  • Physiology 2 （2024academic year） Second semester  - 水5～6

  • Physiology 2 （2024academic year） Second semester  - 水5～6

  • Pharmacology 7 （2024academic year） Third semester  - 金3～4

  • Pharmacology 7 （2024academic year） Third semester  - 金3～4

  • Pharmacology 8 （2024academic year） Fourth semester  - 金3～4

  • Pharmacology 8 （2024academic year） Fourth semester  - 金3～4

  • Pharmacology D （2024academic year） 3rd and 4th semester  - 金3～4

  • Pharmacology D （2024academic year） 3rd and 4th semester  - 金3～4

  • Small Group Discussion for Pharmaceutical Sciences （2024academic year） 1st semester  - 火3～4

  • Small Group Discussion for Pharmaceutical Sciences （2024academic year） 1st semester  - 火3～4

  • Introduction to Drug Research （2023academic year） Second semester  - 月3～4

  • Mechanism and diagnosis of human body （2023academic year） 1st semester  - 月3～4

  • Practice in Clinical and Biopharmaceutical Sciences （2023academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2023academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2023academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2023academic year） Third semester  - その他5～9

  • Practicals: Inflammatory Pharmacology （2023academic year） special  - その他

  • Research Projects: Inflammatory Pharmacology （2023academic year） special  - その他

  • Advanced Lectures: Inflammatory Pharmacology （2023academic year） special  - その他

  • Inflammatory pharmacology （2023academic year） special  - その他

  • Inflammatory pharmacology （2023academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2023academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2023academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2023academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2023academic year） special  - その他

  • Life Science and Clinical Pharmaceutical Science （2023academic year） special  - その他

  • Life Science 3 （2023academic year） special  - その他

  • Physiology （2023academic year） 1st and 2nd semester  - 水5～6

  • Physiology （2023academic year） 1st and 2nd semester  - 水5～6

  • Physiology 1 （2023academic year） 1st semester  - 水5～6

  • Physiology 1 （2023academic year） 1st semester  - 水5～6

  • Physiology 2 （2023academic year） Second semester  - 水5～6

  • Physiology 2 （2023academic year） Second semester  - 水5～6

  • Pharmacology 7 （2023academic year） Third semester  - 金3～4

  • Pharmacology 7 （2023academic year） Third semester  - 金3～4

  • Pharmacology 8 （2023academic year） Fourth semester  - 金3～4

  • Pharmacology 8 （2023academic year） Fourth semester  - 金3～4

  • Pharmacology D （2023academic year） 3rd and 4th semester  - 金3～4

  • Pharmacology D （2023academic year） 3rd and 4th semester  - 金3～4

  • Small Group Discussion for Pharmaceutical Sciences （2023academic year） 1st semester  - 火3～4

  • Small Group Discussion for Pharmaceutical Sciences （2023academic year） 1st semester  - 火3～4

  • Introduction to Drug Research （2022academic year） Second semester  - 月3～4

  • Mechanism and diagnosis of human body （2022academic year） 1st semester  - 月3～4

  • Practice in Clinical and Biopharmaceutical Sciences （2022academic year） Third semester  - その他5～9

  • Practice in Clinical and Biopharmaceutical Sciences （2022academic year） Third semester  - その他5～9

  • Inflammatory pharmacology （2022academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2022academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2022academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2022academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2022academic year） special  - その他

  • Life Science 3 （2022academic year） special  - その他

  • Physiology （2022academic year） 1st and 2nd semester  - 水5～6

  • Physiology （2022academic year） 1st and 2nd semester  - 水5～6

  • Physiology 1 （2022academic year） 1st semester  - 水5～6

  • Physiology 1 （2022academic year） 1st semester  - 水5～6

  • Physiology 2 （2022academic year） Second semester  - 水5～6

  • Physiology 2 （2022academic year） Second semester  - 水5～6

  • Pharmacology 7 （2022academic year） Third semester  - 金3～4

  • Pharmacology 7 （2022academic year） Third semester  - 金3～4

  • Pharmacology 8 （2022academic year） Fourth semester  - 金3～4

  • Pharmacology 8 （2022academic year） Fourth semester  - 金3～4

  • Small Group Discussion for Pharmaceutical Sciences （2022academic year） 1st semester  - 火3～4

  • Small Group Discussion for Pharmaceutical Sciences （2022academic year） 1st semester  - 火3～4

  • Scientific Backgrounds of Medicines （2021academic year） Second semester  - 木1～2

  • Practice in Clinical and Biopharmaceutical Sciences （2021academic year） Third semester  - その他6～9

  • Practice in Clinical and Biopharmaceutical Sciences （2021academic year） Third semester  - その他6～9

  • Principles of biology for university students （2021academic year） Fourth semester  - 火1～2

  • Inflammatory pharmacology （2021academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2021academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2021academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2021academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2021academic year） special  - その他

  • Life Science 3 （2021academic year） Late  - その他

  • Physiology 1 （2021academic year） 1st semester  - 水5,水6

  • Physiology 1 （2021academic year） 1st semester  - 水5,水6

  • Physiology 2 （2021academic year） Second semester  - 水5～6

  • Physiology 2 （2021academic year） Second semester  - 水5～6

  • Pharmacology 7 （2021academic year） Third semester  - 金3,金4

  • Pharmacology 7 （2021academic year） Third semester  - 金3,金4

  • Pharmacology 8 （2021academic year） Fourth semester  - 金3,金4

  • Pharmacology 8 （2021academic year） Fourth semester  - 金3,金4

  • Small Group Discussion for Pharmaceutical Sciences （2021academic year） 1st semester  - 火3,火4

  • Small Group Discussion for Pharmaceutical Sciences （2021academic year） 1st semester  - 火3,火4

  • Scientific Backgrounds of Medicines （2020academic year） Second semester  - 木1,木2

  • Practice in Clinical and Biopharmaceutical Sciences （2020academic year） Third semester  - その他

  • Practice in Clinical and Biopharmaceutical Sciences （2020academic year） Third semester  - その他

  • Principles of biology for university students （2020academic year） Fourth semester  - 火1,火2

  • Inflammatory pharmacology （2020academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2020academic year） special  - その他

  • International Collaborative Pharmaceutical Education(Field Studies Overseas) （2020academic year） special  - その他

  • Life Science 3 （2020academic year） special  - その他

  • Physiology 1 （2020academic year） 1st semester  - 水5,水6

  • Physiology 1 （2020academic year） 1st semester  - 水5,水6

  • Physiology 2 （2020academic year） Second semester  - 水5,水6

  • Physiology 2 （2020academic year） Second semester  - 水5,水6

  • Pharmacology 5 （2020academic year） Third semester  - 月1,月2

  • Pharmacology 5 （2020academic year） Third semester  - 月1,月2

  • Pharmacology 6 （2020academic year） Fourth semester  - 月1,月2

  • Pharmacology 6 （2020academic year） Fourth semester  - 月1,月2

  • Small Group Discussion for Pharmaceutical Sciences （2020academic year） Fourth semester  - 火7,火8

▼display all